Di Giuli Riccardo, Bonzi Camilla M E, Capuano Silvio M, Vaccari Stefano, Bucci Flavio, Fondrini Riccardo, Klinger Marco, Klinger Francesco, Vinci Valeriano
Aesthet Surg J Open Forum. 2025 Jul 8;7:ojaf090. doi: 10.1093/asjof/ojaf090. eCollection 2025.
Postmastectomy breast edema is a common complication in patients undergoing immediate implant-based reconstruction, leading to physical and psychological consequences. Despite its clinical relevance, standardized prophylactic strategies remain lacking.
The authors of this study aim to evaluate the efficacy of an anti-edema formulation containing diosmin, coumarin, and arbutin (Linfadren, Omega Pharma Srl, Italy) in reducing postmastectomy breast edema and improving postoperative outcomes.
A prospective, randomized clinical trial was conducted at a single tertiary care center. Women aged ≥18 years undergoing mastectomy with immediate implant-based reconstruction were randomized (1:1) into 2 groups: control (standard postoperative prophylaxis) and experimental (standard prophylaxis plus Linfadren, Omega Pharma Srl). Mastectomy flap thickness was measured using Vernier calipers, and breast edema symptoms were assessed with the Breast Edema Questionnaire (BrEQ). Follow-up visits were scheduled weekly during the first month, with additional evaluations at 6 weeks and 2 months.
The experimental group demonstrated a significant reduction in mastectomy flap thickness (45.95% decrease at 2 months vs stable or increased thickness in the control group, < .05). BrEQ scores improved more rapidly in the experimental group, reflecting reduced symptoms of breast edema. Pitting edema prevalence was consistently lower in the experimental group compared with the control group throughout the study ( < .05).
In this study, the authors highlight the potential of Linfadren (Omega Pharma Srl) as an effective prophylactic treatment for postmastectomy breast edema. By mitigating edema, this approach may improve postoperative recovery, reduce complications, and enhance patients' quality of life. Further large-scale studies are warranted to validate these findings.
乳房切除术后的乳房水肿是接受即刻乳房植入重建患者常见的并发症，会导致生理和心理方面的后果。尽管其具有临床相关性，但仍缺乏标准化的预防策略。
本研究的作者旨在评估一种含有地奥司明、香豆素和熊果苷的消肿配方（Linfadren，意大利欧米加制药公司）在减轻乳房切除术后乳房水肿及改善术后结局方面的疗效。
在一家三级医疗中心进行了一项前瞻性随机临床试验。年龄≥18岁、接受乳房切除并即刻乳房植入重建的女性被随机（1:1）分为两组：对照组（标准术后预防措施）和试验组（标准预防措施加Linfadren，意大利欧米加制药公司）。使用游标卡尺测量乳房切除皮瓣厚度，并用乳房水肿问卷（BrEQ）评估乳房水肿症状。在第一个月每周安排随访，在6周和2个月时进行额外评估。
试验组乳房切除皮瓣厚度显著降低（2个月时降低45.95%，而对照组厚度稳定或增加，P<0.05）。试验组BrEQ评分改善更快，反映出乳房水肿症状减轻。在整个研究过程中，试验组的凹陷性水肿患病率始终低于对照组（P<0.05）。
在本研究中，作者强调了Linfadren（意大利欧米加制药公司）作为乳房切除术后乳房水肿有效预防性治疗方法的潜力。通过减轻水肿，这种方法可能改善术后恢复、减少并发症并提高患者生活质量。需要进一步的大规模研究来验证这些发现。
